Cargando…

Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden

OBJECTIVE: To compare healthcare costs in chronic kidney disease (CKD) stage 4 or 5 not on dialysis (estimated glomerular filtration rate <30 mL/min/1.73m(2)), peritoneal dialysis, haemodialysis and in transplanted patients with matched general population comparators. DESIGN: Population-based coh...

Descripción completa

Detalles Bibliográficos
Autores principales: Eriksson, Jonas K, Neovius, Martin, Jacobson, Stefan H, Elinder, Carl-Gustaf, Hylander, Britta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5073563/
https://www.ncbi.nlm.nih.gov/pubmed/27855091
http://dx.doi.org/10.1136/bmjopen-2016-012062
_version_ 1782461601744420864
author Eriksson, Jonas K
Neovius, Martin
Jacobson, Stefan H
Elinder, Carl-Gustaf
Hylander, Britta
author_facet Eriksson, Jonas K
Neovius, Martin
Jacobson, Stefan H
Elinder, Carl-Gustaf
Hylander, Britta
author_sort Eriksson, Jonas K
collection PubMed
description OBJECTIVE: To compare healthcare costs in chronic kidney disease (CKD) stage 4 or 5 not on dialysis (estimated glomerular filtration rate <30 mL/min/1.73m(2)), peritoneal dialysis, haemodialysis and in transplanted patients with matched general population comparators. DESIGN: Population-based cohort study. SETTING: Swedish national healthcare system. PARTICIPANTS: Prevalent adult patients with CKD 4 or 5 (n=1046, mean age 68 years), on peritoneal dialysis (n=101; 64 years), on haemodialysis (n=460; 65 years) and with renal transplants (n=825; 52 years) were identified in Stockholm County clinical quality registers for renal disease on 1 January 2010. 5 general population comparators from the same county were matched to each patient by age, sex and index year. PRIMARY AND SECONDARY OUTCOME MEASURES: Annual healthcare costs in 2009 incurred through inpatient and hospital-based outpatient care and dispensed prescription drugs ascertained from nationwide healthcare registers. Secondary outcomes were annual number of hospital days and outpatient care visits. RESULTS: Patients on haemodialysis had the highest mean annual cost (€87 600), which was 1.49 (95% CI 1.38 to 1.60) times that observed in peritoneal dialysis (€58 600). The mean annual cost was considerably lower in transplanted patients (€15 500) and in the CKD group (€9600). In patients on haemodialysis, outpatient care costs made up more than two-thirds (€62 500) of the total, while costs related to fluids ($29 900) was the largest cost component in patients on peritoneal dialysis (51%). Compared with their matched general population comparators, the mean annual cost (95% CI) in patients on haemodialysis, peritoneal dialysis, transplanted patients and patients with CKD was 45 (39 to 51), 29 (22 to 37), 11 (10 to 13) and 4.0 (3.6 to 4.5) times higher, respectively. CONCLUSIONS: The mean annual costs were ∼50% higher in patients on haemodialysis than in those on peritoneal dialysis. Compared with the general population, costs were substantially elevated in all groups, from 4-fold in patients with CKD to 11, 29 and 45 times higher in transplanted patients and patients on peritoneal dialysis and haemodialysis, respectively.
format Online
Article
Text
id pubmed-5073563
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-50735632016-11-07 Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden Eriksson, Jonas K Neovius, Martin Jacobson, Stefan H Elinder, Carl-Gustaf Hylander, Britta BMJ Open Renal Medicine OBJECTIVE: To compare healthcare costs in chronic kidney disease (CKD) stage 4 or 5 not on dialysis (estimated glomerular filtration rate <30 mL/min/1.73m(2)), peritoneal dialysis, haemodialysis and in transplanted patients with matched general population comparators. DESIGN: Population-based cohort study. SETTING: Swedish national healthcare system. PARTICIPANTS: Prevalent adult patients with CKD 4 or 5 (n=1046, mean age 68 years), on peritoneal dialysis (n=101; 64 years), on haemodialysis (n=460; 65 years) and with renal transplants (n=825; 52 years) were identified in Stockholm County clinical quality registers for renal disease on 1 January 2010. 5 general population comparators from the same county were matched to each patient by age, sex and index year. PRIMARY AND SECONDARY OUTCOME MEASURES: Annual healthcare costs in 2009 incurred through inpatient and hospital-based outpatient care and dispensed prescription drugs ascertained from nationwide healthcare registers. Secondary outcomes were annual number of hospital days and outpatient care visits. RESULTS: Patients on haemodialysis had the highest mean annual cost (€87 600), which was 1.49 (95% CI 1.38 to 1.60) times that observed in peritoneal dialysis (€58 600). The mean annual cost was considerably lower in transplanted patients (€15 500) and in the CKD group (€9600). In patients on haemodialysis, outpatient care costs made up more than two-thirds (€62 500) of the total, while costs related to fluids ($29 900) was the largest cost component in patients on peritoneal dialysis (51%). Compared with their matched general population comparators, the mean annual cost (95% CI) in patients on haemodialysis, peritoneal dialysis, transplanted patients and patients with CKD was 45 (39 to 51), 29 (22 to 37), 11 (10 to 13) and 4.0 (3.6 to 4.5) times higher, respectively. CONCLUSIONS: The mean annual costs were ∼50% higher in patients on haemodialysis than in those on peritoneal dialysis. Compared with the general population, costs were substantially elevated in all groups, from 4-fold in patients with CKD to 11, 29 and 45 times higher in transplanted patients and patients on peritoneal dialysis and haemodialysis, respectively. BMJ Publishing Group 2016-10-07 /pmc/articles/PMC5073563/ /pubmed/27855091 http://dx.doi.org/10.1136/bmjopen-2016-012062 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Renal Medicine
Eriksson, Jonas K
Neovius, Martin
Jacobson, Stefan H
Elinder, Carl-Gustaf
Hylander, Britta
Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden
title Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden
title_full Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden
title_fullStr Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden
title_full_unstemmed Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden
title_short Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden
title_sort healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in sweden
topic Renal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5073563/
https://www.ncbi.nlm.nih.gov/pubmed/27855091
http://dx.doi.org/10.1136/bmjopen-2016-012062
work_keys_str_mv AT erikssonjonask healthcarecostsinchronickidneydiseaseandrenalreplacementtherapyapopulationbasedcohortstudyinsweden
AT neoviusmartin healthcarecostsinchronickidneydiseaseandrenalreplacementtherapyapopulationbasedcohortstudyinsweden
AT jacobsonstefanh healthcarecostsinchronickidneydiseaseandrenalreplacementtherapyapopulationbasedcohortstudyinsweden
AT elindercarlgustaf healthcarecostsinchronickidneydiseaseandrenalreplacementtherapyapopulationbasedcohortstudyinsweden
AT hylanderbritta healthcarecostsinchronickidneydiseaseandrenalreplacementtherapyapopulationbasedcohortstudyinsweden